Natco Pharma up 4%, launches hepatitis C drug in Nepal


Source: Money Control

10 Mar 2015

Shares of  Natco Pharma  gained 4.4 percent intraday on Monday on launching the first generic version of sofosbuvir in Nepal.

Sofosbuvir is a medicine used for chronic hepatitis C infection and sold globally by Gilead Sciences Inc., under its brand Sovaldi. Natco priced its generic medicine at an MRP of Rs 19,900 for a bottle of 28 tablets in Nepal.

“Natco markets generic sofosbuvir under its brand HEPCINAT. Natco hopes to launch HEPCINAT in India soon, subject to approval from the Drugs Controller General of India (DCGI),” said the company in its filing to the exchange. Natco had recently signed a non-exclusive licensing agreement with Gilead Sciences, to manufacture and sell generic versions of its chronic hepatitis C medicines in 91 developing countries.

At 10:22 hours IST, the scrip of Natco Pharma was quoting at Rs 1,537, up Rs 23.45, or 1.55 percent on the BSE.

Posted by Sunil Shankar Matkar

This entry was posted in Generics, Hepatitis C, Sofosbuvir. Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s